IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

CPhI Worldwide: Saltigo Adds High-Potency Capability in the U.S., Boosts Prospects for Japanese Market

8:03 AM MDT | October 27, 2011 | Alex Scott in Frankfurt

Saltigo, the custom manufacturing arm of Lanxess, says it will build new manufacturing facilities at Redmond, WA for manufacturing highly potent active pharma ingredients (HPAPI). The facility has been designed to meet the needs of the firm’s U.S. pharmaceutical customers. It is set to manufacture category III and category IV highly potent drugs up to the kilogram level from the beginning of 2012. Once the facility is operational Saltigo will be able to manufacture active ingredients with an occupational exposure limit (OEL) of less than 10 micrograms/cu m...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa